Ingela Hallberg
Chief Tech/Sci/R&D Officer at Aptahem AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Artur Bernardino Aira | M | 57 |
University of Gothenburg
| 10 years |
| Knut Mikael Ingolf Lindstam | M | 58 |
Aptahem AB
 Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 10 years |
| Bert Roland Kari Junno | M | 58 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Johan Lindh | M | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 10 years |
| Lotta Bus | F | 54 | 4 years | |
| Christian Wildmoser | M | 68 | 5 years | |
| Helena Margareta Skåntorp | F | 64 | 5 years | |
| Theresa Comiskey Olsen | F | 61 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Luiza Jedlina | M | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 10 years |
| Ulla Cristina Glad | M | 72 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 8 years |
| Jan Nilsson | M | 56 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Ola Skanung | M | 60 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Maria Ekblad | F | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 2 years |
| Suzanne Kilany | F | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
| Åsa Kornfeld | F | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Carsten Nils Erik Browall | M | 66 | - | |
| Johan Wilhelmsson | M | - |
University of Gothenburg
| 4 years |
| Melanie Lee | M | 65 | 3 years | |
| Aristotelis Nastos | M | 56 | - | |
| Isabelle Ljunggren | F | - | 1 years | |
| Peter Henrik Kürstein-Jensen | M | 68 | 11 years | |
| Björn Stansvik | M | - |
University of Gothenburg
| 6 years |
| Lennart Ekelund | M | 65 |
University of Gothenburg
| 2 years |
| Anders Johan Fredrik Düring | M | 59 |
University of Gothenburg
| 1 years |
| Torsten Meldgaard Madsen | M | 57 | 4 years | |
| Anna Cecilia Malmstrom | M | 56 |
University of Gothenburg
| 4 years |
| Elisabeth Gilert | M | - |
University of Gothenburg
| 3 years |
| Jonas Schoendube | M | 39 | - | |
| Peter Sterky | M | - |
University of Gothenburg
| 3 years |
| Björn Skytt | M | 50 |
University of Gothenburg
| 4 years |
| Olof Gustaf Paulus Isaksson | M | 81 |
University of Gothenburg
| - |
| Thorbjörn Johansson | M | - | 1 years | |
| Magnus Thorstholm Jensen | M | - | 5 years | |
| Anders Bylock | M | 70 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 4 years |
| Martin Soderberg | M | - |
University of Gothenburg
| 4 years |
| Torben Thölix | M | - | 1 years | |
| Fredrik Adolfsson | M | - |
University of Gothenburg
| 5 years |
| Niclas Emanuelsson | M | 53 | 2 years | |
| Annika Westlund | F | - |
University of Gothenburg
| 2 years |
| Mats Eklund | M | - |
University of Gothenburg
| 4 years |
| Marie Reinius | F | - |
University of Gothenburg
| 4 years |
| Pia Renaudin | F | 57 |
University of Gothenburg
| 2 years |
| João Carlos Nunes Rocha | M | 66 | - | |
| Barbara Jaszewski | F | 65 | - | |
| Thomas Hedner | M | 75 |
University of Gothenburg
| 23 years |
| Ulf Gunnar Ivarsson | M | 63 |
University of Gothenburg
| 3 years |
| Neil Meredith | M | - |
University of Gothenburg
| 4 years |
| Holger Eickhoff | M | 59 | - | |
| Marie Lindebäck | F | 52 |
University of Gothenburg
| 4 years |
| Erik Karl-Johan Willén | M | - |
University of Gothenburg
| 4 years |
| Charlotta Modig | F | - |
University of Gothenburg
| 4 years |
| Per Fredrik Wester | M | 50 |
University of Gothenburg
| 5 years |
| Yi Wang | M | - |
University of Gothenburg
| 3 years |
| Vincent Aurentz | M | 56 |
IQVIA Clinical AB
 IQVIA Clinical AB Pharmaceuticals: MajorHealth Technology IQVIA Clinical AB delivers information and technology solutions for healthcare purposes. It specializes in primary care, hospital, and specialist products. The company was founded in 1984 and is headquartered in Solna, Sweden. | 2 years |
| Klementina Österberg | F | 49 |
University of Gothenburg
| 4 years |
| Carl Jesper Olof Hen Bergqvist | M | 52 |
University of Gothenburg
| 6 years |
| Martin Chul Martin Creydt | M | 59 |
University of Gothenburg
| 3 years |
| Lars Lönn | M | 68 |
University of Gothenburg
| 3 years |
| Åslög Dahl | M | - |
University of Gothenburg
| 3 years |
| João Manuel de Matos Loureiro | M | 64 |
University of Gothenburg
| 3 years |
| Lennart Ove Mikael Karlsson | M | 61 |
University of Gothenburg
| 2 years |
| Rickard Brånemark | M | 64 |
University of Gothenburg
| 3 years |
| Peter Juhnke | M | - |
University of Gothenburg
| 4 years |
| Marie-Laure Jeanne Antoinette Pochon | F | 65 | 5 years | |
| Nils Joakim Gustafson von Heijne | M | - |
University of Gothenburg
| 1 years |
| Tony Winslöf | M | 60 |
University of Gothenburg
| 4 years |
| Caroline Farberger | F | - |
University of Gothenburg
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 60 | 89.55% |
| Denmark | 7 | 10.45% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ingela Hallberg
- Personal Network
